Unlock instant, AI-driven research and patent intelligence for your innovation.

Drug for treating myasthenia gravis as well as preparation method and application thereof

A myasthenia gravis and medicine technology, applied in the field of medicine, can solve problems such as easy recurrence and strong drug dependence, and achieve the effect of no toxic side effects, treatment of myasthenia gravis, and simple preparation method

Inactive Publication Date: 2018-10-26
吕芳芳
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the existing traditional Chinese medicine has the disadvantage of strong drug dependence, and once the drug is stopped, it is easy to relapse

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] A medicine for treating myasthenia gravis, the medicine for treating myasthenia gravis comprises the following components in parts by weight: 21 parts of Spiraea alpine, 12 parts of Hovenia dulcis, 6 parts of bamboo fungus extract, stephenine hydrochloride 5 parts, hypericin 6 parts, diguanosine tetraphosphate 4 parts.

[0026] A method for preparing a medicine for treating myasthenia gravis, comprising the following steps: (1) preparing the extract of Dictyophora: extracting Dictyophora by ethanol; Elute with water and 85% ethanol, collect the eluate, and dry under reduced pressure to obtain the extract of Dictyophora; the ratio of the amount of Dictyophora to resin is that 1kg of medicinal materials requires 500ml of macroporous resin pretreated by swelling with absolute ethanol; The model of the macroporous adsorption resin is D101, the resin column diameter-to-height ratio is 1:5, the sample loading flow rate is 0.2BV / h, and the elution flow rate is 1BV / h; Alkali m...

Embodiment 2

[0028] A medicine for treating myasthenia gravis, the medicine for treating myasthenia gravis comprises the following components in parts by weight: 30 parts of Spiraea alpine, 20 parts of Hovenia dulcis, 15 parts of bamboo fungus extract, stephenine hydrochloride 11 parts, hypericin 12 parts, diguanosine tetraphosphate 8 parts.

[0029] A method for preparing a medicine for treating myasthenia gravis, comprising the following steps: (1) preparing the extract of Dictyophora: extracting Dictyophora by ethanol; Elute with water and 85% ethanol, collect the eluent, and dry under reduced pressure to obtain the extract of Dictyophora; the ratio of the amount of Dictyophora to resin is that 1kg of medicinal materials requires 550ml of macroporous resin pretreated by swelling with absolute ethanol; The model of the macroporous adsorption resin is D101, the diameter-to-height ratio of the resin column is 1:7, the loading flow rate is 0.6BV / h, and the elution flow rate is 3BV / h; Alkal...

Embodiment 3

[0031] A medicine for treating myasthenia gravis, the medicine for treating myasthenia gravis comprises the following components in parts by weight: 25 parts of Spiraea alpine, 16 parts of Hovenia dulcis, 10 parts of bamboo fungus extract, stephenine hydrochloride 8 parts, hypericin 9 parts, diguanosine tetraphosphate 6 parts.

[0032] A method for preparing a medicine for treating myasthenia gravis, comprising the following steps: (1) preparing the extract of Dictyophora: extracting Dictyophora by ethanol; Elute with water and 85% ethanol, collect the eluent, and dry under reduced pressure to obtain the extract of Dictyophora; the ratio of the amount of Dictyophora to resin is that 1kg of medicinal materials requires 520ml of macroporous resin pretreated by swelling with absolute ethanol; The model of the macroporous adsorption resin is D101, the diameter-to-height ratio of the resin column is 1:6, the sample loading flow rate is 0.5BV / h, and the elution flow rate is 2BV / h. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug for treating myasthenia gravis as well as a preparation method and application thereof. The drug for treating the myasthenia gravis is prepared from the following components in parts by weight: 21 to 30 parts of flos spiraeae salicifoliae, 12 to 20 parts of semen hoveniae, 6 to 15 parts of bamboo fungus extract, 5 to 11 parts of cepharanthine hydrochloride, 6 to 12 parts of hypericin, and 4 to 8 parts of diguanosine tetraphosphate. The drug is prepared from the flos spiraeae salicifoliae, semen hoveniae, bamboo fungus extract, cepharanthine hydrochloride, hypericin and diguanosine tetraphosphate and can effectively treat the myasthenia gravis, and after the drug is stopped, the myasthenia gravis is unlikely to reoccur; the drug is basically nontoxic and freefrom side effect and safer; and the preparation method is simple and favorable for popularization.

Description

technical field [0001] The invention relates to a medicine, in particular to a medicine for treating myasthenia gravis, a preparation method and application. Background technique [0002] Myasthenia gravis (MG) is an autoimmune disease caused by dysfunction of the nerve-muscle junction. The main clinical manifestations are partial or general skeletal muscle weakness and easy fatigue. The symptoms are aggravated after activities and relieved after rest. . The prevalence rate of women is higher than that of men, and the disease occurs in all age groups, most of which are children aged 1-5. [0003] The main clinical manifestations are partial or general skeletal muscle weakness and easy fatigue, and the symptoms are aggravated after activities, and the symptoms are relieved after rest and cholinesterase inhibitor treatment. Patients with myasthenia gravis often have other autoimmune diseases such as hyperthyroidism, thyroiditis, systemic lupus erythematosus, rheumatoid arthr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/73A61P21/04A61K31/4741A61K31/122A61K31/708
CPCA61K31/122A61K31/4741A61K31/708A61K36/07A61K36/72A61K36/73A61K2236/33A61K2236/51A61K2236/55A61P21/04A61K2300/00
Inventor 吕芳芳
Owner 吕芳芳